Hypertension
Conditions
Keywords
soybean peptides, clinical trial, blood preesure, SBP, DBP
Brief summary
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Overall, soybean peptide consumption for 8 weeks could successfully reduce mean diastolic and systolic BP through the suppression of Angiotensin-converting enzyme (ACE) linked to downstream suppression of angiotensin II formation, which further decreases the sympathetic outflow that leads to hypertension.
Detailed description
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Thirty subjects with systolic blood pressure (SBP) between 120 and 159 mm Hg and/or diastolic blood pressure (DBP) between 80 and 99 mm Hg were randomized to ingest 2 bags of soybean peptides or placebo per day for 8 weeks of a stage. Anthropometric measurements (blood pressure, body weight, body fat) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT) were examined every four weeks.
Interventions
DIETARY_SUPPLEMENTSoybean peptides
Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
DIETARY_SUPPLEMENTPlacebo
Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
Sponsors
Chung Shan Medical University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Eligible subjects were untreated hypertensive men or women aged between 20 and 80 years old with SBP between 120 and 159 mmHg and/or DBP between 80 and 99 mmHg as measured in a sitting position
Exclusion criteria
* Subjects were excluded if they had a history of major cardiovascular disease or severe liver dysfunction; * Diastolic blood pressure ≥ 100 mmHg or Systolic blood pressure ≥ 160 mmHg; * Alcoholic; * US-controlled diabetics; * Stoke in past one year; * Mental diseases or melancholia; * Pregnancy or breast-feeding a child; * Renal dysfunction; * Allergic to Soybean peptides.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The soy bean peptides anti-hypertensive measure blood pressure (SBP and DBP) | 8 weeks | values chang of systolbbic and diastolic BPs between before to after 8 weeks |
Countries
Taiwan
Outcome results
None listed